Print this page
-
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors.
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors.
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Protocol: 052504Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Protocol: 052504Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors.
Protocol: 052505Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors.
Protocol: 052505Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability,
Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination
Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability,
Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination
Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors.
Protocol: 052508Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors.
Protocol: 052508Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors.
Protocol: 052509Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Esophagus
Lung
Other Digestive Organ
Pancreas
Thyroid -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Colon
Esophagus
Ill-Defined Sites
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach
Unknown Sites -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Colon
Esophagus
Ill-Defined Sites
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach
Unknown Sites -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Applicable Disease Sites: Any Site
-
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Applicable Disease Sites: Any Site